Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

The impact of a co-payment increase on the consumption of type 2 antidiabetics – A nationwide interrupted time series analysis

Katri Aaltonen; Terhi Kurko; Hanna Rättö; Jaana E. Martikainen

The impact of a co-payment increase on the consumption of type 2 antidiabetics – A nationwide interrupted time series analysis

Katri Aaltonen
Terhi Kurko
Hanna Rättö
Jaana E. Martikainen
Katso/Avaa
HP2021.pdf (744.1Kb)
Lataukset: 

Elsevier B.V.
doi:10.1016/j.healthpol.2021.05.007
URI
https://www.sciencedirect.com/science/article/pii/S0168851021001342
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021093048156
Tiivistelmä

International literature suggests
that co-payment increases are associated with decreased medicine use,
although the effects depend on context. We examined the impact of a
co-payment increase on the consumption of type 2 antidiabetics in
Finland, a country with a comprehensive health and social security
system including ceiling mechanisms aiming to protect patients from high
co-payment expenditures.

We used administrative
register data on all reimbursed purchases of antidiabetics during
2014−2018. An interrupted time series design with segmented regression
was used to examine the mean monthly purchase per person, measured as
Defined Daily Doses (DDDs), before and after the co-payment increase.

At baseline, the mean monthly purchase per person of type 2 antidiabetics was 105 DDDs (95% CI 103.8; 106.0;p<0.001) and there was a decreasing trend of 0.2 DDDs per month (95% CI -0.23;-0.13;p<0.001). A statistically significant decrease of 5.6 DDDs (95% CI -7.3;-3.8;p<0.001)
was detected after the reform; however, no significant change in the
trend was observed. No significant increase was detected in the mean
monthly per person purchase of insulins.

The results
suggest that a co-payment increase decreases consumption of necessary
medicines despite the presence of a medicine co-payment ceiling
mechanism. Whether the decrease was associated with negative health
effects remains to be further investigated.

Kokoelmat
  • Rinnakkaistallenteet [19207]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste